MIMEDX
Most popular related searches
negative pressure wound therapy
hyperbaric oxygen therapy
wound bed
allograft
hyperbaric oxygen
biorepository
wound therapy
surgery system
biocompatibie
healing improvement
- A semi-permeable protective barrier that supports the healing cascade
- Protects the wound bed to aid in the development of granulation tissue
- Provides a human biocompatible extracellular matrix
300+ regulatory proteins1-3
- SMR2T™ Technology and patented PURION processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)
- Comorbid patients with complex defects or delayed healing
- Debridements, amputations, dehiscence, flaps, decubitus ulcers, trauma, pilonidal cysts, port sites and burns
AMNIOFIX is processed using PURION, a unique patented method for placental-based allografts that is in accordance with the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.
AMNIOFIX is SMR2T Technology (Selective Membrane of Reparative and Reconstructive Tissue) which provides a semi-permeable protective barrier that supports the healing cascade. The product protects the wound bed to aid in the development of granulation tissue and provides a human biocompatible extracellular matrix that retains 300+ regulatory proteins.1-3